Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
BACKGROUND: mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. METHODS: We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. RESULTS: Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol per liter]), whereas patients receiving placebo had an 18% increase in mean triglyceride levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) (95% CI, -301.0 to 486 mg per deciliter [-3.4 to 5.5 mmol per liter]) (P<0.001). At 3 months, 77% of the patients in the volanesorsen group, as compared with 10% of patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter (8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients who received placebo had such reactions. No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who had levels below 25,000 per microliter. No patient had platelet counts below 50,000 per microliter after enhanced platelet-monitoring began. CONCLUSIONS: Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 15 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data show that volanesorsenmediated lowering of apolipoprotein C-III effectively enhances clearance of triglyceride-rich lipoproteins in patients without LPL activity.27”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) states that volanesorsen 'dramatically lowered elevated plasma TG levels in patients who have genetic defects in LPL (familial chylomicronemia syndrome [FCS])' and that, despite the absence of a placebo control group, 'this finding suggests that ApoC-III impairs TG clearance predominantly in an LPL-independent fashion'; the Discussion adds that their mouse data are 'consistent with the recent observation that targeting of ApoC-III effectively reduces plasma TGs in LPL-deficient patients'. So the enhanced-clearance-in-LPL-deficient-patients reading is present, but the source hedges it as a suggestion inferred from TG lowering (clearance itself was measured only in mice) and explicitly flags the uncontrolled design; the Discussion also notes the FCS subjects had a mutated LPL with possible residual activity rather than a strict absence. The citing sentence's unhedged 'these data show ... effectively enhances clearance' therefore overstates what this source attributes to the trial. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Not checked yetcites [6] source
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Our copy of the NLA Part 2 recommendations contains no mention of volanesorsen, apolipoprotein C-III as a therapeutic target, or the APPROACH trial (searched: 'volanesorsen APPROACH trial apolipoprotein C-III familial chylomicronemia syndrome', 'apolipoprotein C-III antisense oligonucleotide new therapies', 'severe hypertriglyceridemia pancreatitis threshold'). The closest passages cover only established therapy for very high TG — the 'Dietary considerations for management of hypertriglyceridemia' and 'Targets of lifestyle therapies' sections set the pancreatitis-prevention goal at lowering TG to <500 mg/dL (noting chylomicronemia is often present at ≥750 mg/dL), and the 'Non-statin recommendations' / 'Fibrates' sections discuss fenofibrate and prescription omega-3s — so nothing here speaks to the trial result attributed to this source. Our copy is also flagged as truncated, so the decisive text may be missing. (LLM, conf=0.72)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
Our copy of the 2012 Endocrine Society guideline contains no mention of volanesorsen, the APPROACH trial, or an antisense apoC-III oligonucleotide (searched: 'volanesorsen APPROACH trial apolipoprotein C-III antisense', 'antisense oligonucleotide apoC-III inhibitor', '750 mg/dl triglyceride threshold'); apoC-III appears only in pathophysiology/kinetics references. Nor does it give a 750-880 mg/dl pancreatitis threshold: the Chylomicronemia syndrome section states pancreatitis risk 'markedly increases with very severe triglyceride levels above 2000 mg/dl' and 'can be prevented by maintaining triglyceride levels below 1000 mg/dl', and the Fibrates section sets a treatment goal of <1000 mg/dl. The trial result attributed here is therefore not addressed by this source at all (the guideline predates the APPROACH trial), so the claim cannot be checked against it. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“findings that support the hypothesis that apolipoprotein C-III also inhibits an LPL-independent pathway of triglyceride-rich lipoprotein clearance.16”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > F
What the sources say
- Supportedcites [16] source
The Discussion says the study's findings suggest that APOC3 regulates triglyceride-rich lipoprotein metabolism through LPL-independent pathways. The Figure 2 caption states more specifically that APOC3 has an inhibitory role in that pathway, matching the citing sentence's hypothesis. (LLM, conf=0.94)
hedgedstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three other patients with lesser grades (grade 1 or 2) of decreased platelet counts were withdrawn from the trial because of concerns on the part of the site investigators.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourteen patients assigned to volanesorsen, as compared with 2 patients assigned to placebo, did not complete the 52-week trial”
- Also stated in: § 541 · plain
“Fourteen patients in the volanesorsen group discontinued the trial: 9 because of adverse events that occurred during treatment (including 5 who had decreases in platelet counts and 4 because of other drug-related side effects), and 5 primarily because of issues related to requirements of the protocol.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 541 · plain
22 more claims
Create a free account to see all 79 claims and to verify the 23 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are consistent with the observations that LDL cholesterol levels are typically very low (<20 mg per deciliter [0.52 mmol per liter]) and total apolipoprotein B levels are within the low-to-normal range in persons with familial chylomicronemia syndrome. 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous trial involving patients with familial chylomicronemia syndrome, the administration of volanesorsen at a weekly dose of 300 mg per deciliter over a 3-month period was accompanied by reductions in apolipoprotein C-III and triglyceride levels of 84% and 77%, respectively, 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While APPROACH was not powered to detect clinical endpoints, exploratory analyses showed a meaningful reduction in pancreatitis episodes among patients who achieved sustained TG levels below 500 mg/dL— considered by some to be a threshold for pancreatitis risk [44].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its safety profile, particularly the high incidence of thrombocytopenia, has limited broader clinical adoption [115]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced platelet counts below 100 000 per microliter was a common adverse event in the volanesorsen group (15 of 33 patients, two patients with levels < 25 000 per microliter).74”
From Clinical review on triglycerides (2020) · cites this paper as [74]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Abstract
“15 of 33 patients in the volanesorsen group had such levels”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
“confirmed nadir levels below 100,000 per microliter were observed in 16 patients (48%) who received volanesorsen”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“1933 mg per deciliter [22.5 mmol per liter]”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Secondary Efficacy End Points
Reported 22.5 · recomputed 21.82357
Citations
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationIssues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
Research works printed but not linked: 1
- Brunzell JD Deeb SS. Familial lipoprotein lipase deficiency apo CII deficiency and hepatic lipase deficiency. In: Scriver CR Beaudet AL Sly WS et al. eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill 2000:2789-816.
Cited by
Items 601–673 of 673
Developing therapeutics for rare cardiovascular diseases
Lerman, J. B., Koeberl, D. D., Epstein, S., Roessig, L., Stan, R., Halley, M. C., OWENS, A. T., Greenberg, B., Alexander, K. M., Day, S. M., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.09.004
Pancreatitis aguda secundaria a quilomicronemia multifactorial no hereditaria
Alfaro, L., & Cruz, K. (2025) · Revista médica (Colegio de Médicos y Cirujanos de Guatemala) · doi:10.36109/qvm35931
Новый патогенный генетический вариант в гене LPL у пациентки компаунд-гетерозиготы с хиломикронемией
Prus, Y. A., Нозадзе, Д. Н., Васильев, П. А., Ivanova, O. N., Захарова, Е. Ю., & Sergienko, I. V. (2025) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2025.03.0008
RNA Therapeutic Agents as a New Generation of Drugs for the Treatment of Cardiovascular Diseases
Айтбаев, К. А., Murkamilov, I. T., Yusupov, А., Raimzhanov, Z. R., Абдилалимовна, М. Ж., Yusupov, F. A., Yusupova, T. F., Zakirov, O. T., Khabibullaev, K. K., & Abdibaliev, I. A. (2025) · Bulletin of Science and Practice · doi:10.33619/2414-2948/119/17
Александровна, С. О. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.5.008
Familial chylomicronemia in children: clinical cases
Sadykova, D. I., Рашидовна, С. Д., Шакирова, А. Р., Sayfullina, R. M., Damotsev, I. V., Bulatova, А. K., Gagieva, Z. A., Хабибрахманова, З. Р., & Сластникова, Е. С. (2025) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2025-70-5-91-96
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Jadrníčková, P., Tichý, L., Kašpráková, M. M., Václavík, P. M. J., & Freiberger, T. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.016
Makhmudova, U., Schulze, P. C., Lorkowski, S., März, W., Geiling, J.-A., & Weingärtner, O. (2024) · Figshare · doi:10.6084/m9.figshare.26732413
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26170673
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742758
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742767
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742749
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742770
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046914
Self-citationZhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742755
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26170609
Iitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Figshare · doi:10.6084/m9.figshare.13297272
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046917
Self-citationZhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742764
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742752
Zhang, Y., Jiang, Z., Chen, L., Lei, T., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26742761
Feroz, K., Parvez, A., Ramzan, N. U. H., Asghar, T., Cheema, A. H., Malik, A. P., Fatima, T., Iqbal, J., & Sathian, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/9984822
“The most signi fi cant side e ff ects reported in clinical trials of volanesorsen were episodes of severe thrombocytopenia of up to 25,000 platelets per microliter and associated thrombocytopenic events leading to discontinuation of drug [34].”
Fujioka, Y., Tanaka, S.-I., Tsujino, T., Ishida, T., & Hirata, K. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66073
Wie lässt sich das Pankreatitisrisiko senken?
Klose, G. (2026) · Gastro-News · doi:10.1007/s15036-025-3968-9
The hidden burden of kidney damage in chylomicronemia syndromes
D’Erasmo, L., Tramontano, D., Costanzo, A. D., Bini, S., Pasquali, M., Commodari, D., Arizaj, I., Pecce, V., Cerbelli, B., Minicocci, I., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120621
Self-citationLe syndrome d’hyperchylomicronémie familiale (SHF)
Langlois, C., & Charrière, S. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.01.003
Vega, J. A., Torres, B., Alberto Maiz, G., & Santos, J. L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1749264
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Harangi, M., Nádró, B., Diószegi, Á., & Paragh, G. (2026) · Magyar Belorvosi Archívum · doi:10.59063/mba.2026.79.1.2
Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique
Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009
Vergès, B. L. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48948-8
Progress and Prospects of APOC3-Targeted siRNA Drugs in Coronary Artery Disease Research
黄, 林. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631183
Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.052
Horwacik, J., Maligłówka, M., Bułdak, Ł., & Okopień, B. (2026) · Livers · doi:10.3390/livers6020025
“The phase 3, placebo-controlled, double-blind, randomized trial for participants with FCS (APPROACH, NCT02211209) showed a sustained 77% decrease in TG levels in the volanesorsen group, compared with an 18% increase in the placebo group ( p 0.001) [107].”
InfluentialSymptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life
Aboheimed, G. I., AlRasheed, M. M., AlFattani, A. A. G., Alhusayn, K. O., Alali, S., khbiah, R. A. A., Çolak, D., Al-Ashwal, A. A., & Kaya, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.021
Lambert, J.-M. (2020) · theses.fr (ABES) · doi:10.70675/88a9e212z7d11z4320z85fezc721206a3ff6 · Cited by 1
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
“Mechanistically, thrombocytopenia was attributed to the unconjugated ASO chemistry and off-target interactions with platelets and the innate immune system [56], limitations that directly informed the development of next-generation, hepatocyte-targeted ASOs.”
Emara, A., Awashra, A., Aboeldahab, H. A., Gadelmawla, A. F., Abdul‐Hafez, H. A., Alharran, A. M., Alsubaiei, A. A., AlRumaihi, M. J., Albuhmaid, S. A., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70220
“By contrast, the older agent volanesorsen, though effective in lowering lipids, was limited by dose-related thrombocytopenia, showing how advances in drug chemistry and targeted delivery have improved the safety of ApoC-III inhibitors [31, 32].”
Епидемиология на фамилен хиломикронемичен синдром
Стефанов, Г., & Георгиева, М. (2026) · Редки болести и лекарства сираци · doi:10.36865/2026.v17i1.240
Ergun, N. Ü., & Aslantaş, M. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0123
“Emerging therapies include antisense oligonucleotides targeting apolipoprotein C-III, such as volanesorsen [13].”
Treatment Target Discovery From Vasculo-Protective Phenotypes
Lee, S. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.240
“6,7 Thereafter, pharmacological APOC3 inhibitors were developed 8 and approved in some countries for patients with familial chylomicronemia syndrome.”
Khalil, I., Hossain, M. I., Khalid, A. A., & Sarker, P. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10019-3
“This profile compares favorably to two related treatments: volanesorsen, which was limited by thrombocytopenia and injection-site reactions, and to ploza-siran, which has shown mild liver enzyme changes in some studies [8, 9].”
Masana, L., Ribalta, J., & Ibarretxe, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00102-6
Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis
Patel, V., Sohail, R., Alam, M., Chaudhry, S., Mehdi, S., Patel, S., Patel, R., Khattak, R., Khan, Z., & Patel, M. (2026) · World Journal of Cardiology · doi:10.4330/wjc.121611
Soran, H., Kessler, A. S., Vera-Llonch, M., Alexander, V. J., Serafini, P., Pushkarna, D., Rodrigues, E., Stroes, E. S. G., Schatz, U., Kassner, U., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0069 · Cited by 1
“The placebo-anchored MAIC [17] was conducted using IPD from the Balance [15] study and aggregate-level data from the APPROACH [19] trial.”
InfluentialSelf-citationBerrocal, C., Rodríguez, J. C., Carrascal, A., Gomez, D. V. J., Lafont, E. M. P., Pérez, M. A. R., & Garcia-Ramos, A. F. (2026) · Cureus · doi:10.7759/cureus.111306
“In the phase 3 APPROACH trial, volanesorsen reduced fasting triglycerides by 77% at three months (mean absolute reduction of -1,712 mg/dL) compared to an 18% increase in the placebo group, with 77% of treated patients achieving triglyceride levels below 750 mg/dL versus 10% in the placebo arm [16].”
Mourre, F., & Béliard, S. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.05.002
Clinical Pharmacology of Plozasiran
Huston, J., Orey, D., Corona, K., Ashchi, A., Ashchi, A., Deeb, E., Deeb, A., Rouhbakhsh, R., Berner, J., Sutton, D., et al. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00808-6
“It is important to note the safety considerations for volanesorsen as it requires frequent platelet monitoring due to its association with thrombocytopenia (ranging between grade 1–4 severity in the APPROACH study) [29, 30].”
Kassem, B. A., Shaik, F. A., Sorour, O., Abdelhamid, A. H., Fazal, A., Dakroub, A. H., & Eid, A. H. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001846
Björnson, E., & Adiels, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01442-y
“Volanesorsen, an antisense oligonucleotide targeting APOC3, markedly lowered triglycerides in familial chylomicronemia syndrome [59].”
Labenz, J., & Madisch, A. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2869-1150
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Self-citationChan, S. Y. C., Yau, H. C., Chan, K. Y., & Fu, A. (2026) · Cureus · doi:10.7759/cureus.114010
“Inhibition of apolipoprotein C-III (APOC3) has shown particular promise: volanesorsen achieves substantial triglyceride reduction but is limited by adverse effects, notably thrombocytopenia [20,21].”
Nanomaterials in Cardiovascular Applications
Singh, S. R., Thokchom, B., Bhavi, S. M., Abbigeri, M. B., Kulkarni, S. R., Padti, A. C., & Yarajarla, R. B. (2026) · Advanced structured materials · doi:10.1007/978-981-92-1034-3_11
Park, D.-D., Bühler, A., Schöllhorn, C., & Just, S. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2716800
Neue Strategien der Lipidtherapie: Implikationen des ESC/EAS-Updates 2025
Schneider, T., & Laufs, U. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2676-2694
Forrest, A. S., Majety, P., Mayer, S., & Ganda, O. P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71180
Coan, A. C. C., Katsuyama, E. S., Lopes, R. A., Sanchez, C. V., Prata, A. A., Fukunaga, C. K., Talavera, A., & Shapiro, M. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105022
Characterization of metabolically healthy and unhealthy obesity by circulating omics
Pontali, G., Weichenberger, C. X., Rainer, J., Hantikainen, E. M., Graeve, M. D., Mattivi, F., Kob, M., Ralser, M., Pramstaller, P. P., & Domingues, F. S. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104998
Remnant clearance capacity: a new framework for early type 2 diabetes pathogenesis
Nakajima, K., Murakami, M., & Tanaka, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121345 · Cited by 1
Therapeutic oligonucleotides as genetic medicines: The current state and future perspective
Godinho, B. M. D. C., Ferguson, C. M., & Aartsma-Rus, A. M. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103058 · Cited by 1
To test or not to test: Indications and actionability in lipid genetics
Hegele, R. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.023
Chooklin, S., & Chuklin, S. S. (2026) · Gastroenterology report · doi:10.1093/gastro/goag107
“…once weekly or placebo for 52weeks: four AP episodes occurred in three placebo recipients vs one episode in one volanesorsen recipient; in a post-hoc sub-group with at least two attacks in the preceding 5 years, 0/7 vol-anesorsen recipients vs 3/4 placebo recipients experienced an attack [100].”
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“Recent progress in targeted therapies directed at targets such as apoC-III and ANGPTL3 has created new possibilities for mechanism-and phenotype-based precision intervention in HTG [ 207, 208 ].”
Tsimikas, S., Yang, X., Waldman, E., Lyu, F., Alexander, V. J., & Marcovina, S. M. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101164
Self-citationJurek, B., Winter, J. J., & Quintana, D. S. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1938379
Yu, S., Gong, X. Q., Yang, Y., Duan, Y., Zhang, S., Wang, Y., Wang, Z., Bi, C., & Sun, H. (2026) · Science Advances · doi:10.1126/sciadv.aea2001
“In this study, we designed a gapmer ASO targeting SUV39H2 exon 2 with a similar structure to Food and Drug Administration–approved ASOs ( 54 , 55 ).”
Valle, C. D., Zuin, M., & Bilato, C. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70267
“…Apo C-III, reduces triglycerides by 70%–80% in patients with very high levels of triglycerides such as those with familial chylomicronemia syndrome [107] and is authorized in the European Union for adults with genetically confirmed familial chylomicronemia syndrome (FCS) at high risk of…”
Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01472-6
“The LPL-independent mechanism was demonstrated in patients with FCS, who have virtually absent LPL activity but still achieve marked triglyceride lowering with apoC-III inhibition [5].”
InfluentialProta, D. C. G. (2026) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v29i4.7236
Doi, T., Afzal, S., Jensen, G. B., & Nordestgaard, B. G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121944
Yin, Y., Fan, L., Wan, R., Sun, B., Xiong, B., Zhuang, W., He, D., Bai, H., & Wang, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03072-x
Metadata
- Authors
- Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., Stroes, E. S. G., Bergeron, J., Soran, H., Civeira, F., Hemphill, L., Tsimikas, S., Blom, D. J., O’Dea, L., & Bruckert, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- From the Department of Medicine, University of California San Diego, La Jolla (J.L.W., S.T.), and Ionis Pharmaceuticals, Carlsbad (V.J.A., Q.Y., S.G.H., R.S.G., S.T.) — both in California; the Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, QC (D.G.), and the Department of Medicine and Laboratory Medicine, Centre Hospitalier Universitaire de Québec–University Laval, Quebec, QC (J.B.) — both in Canada; the Department of Medicine, Beth Israel Deaconess Medical Center (S.D.F....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-08
- Volume
- 381
- Issue
- 6
- Pages
- 531-542
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2966503756
- Semantic Scholar
- 1b419fba1e6af00f305b1f8b0ee92c239fec7d40
- Cited by
- 669
- References
- 34
- Citations by year
- 2026: 88 · 2025: 112 · 2024: 112 · 2023: 77 · 2022: 95 · 2021: 91 · 2020: 79 · 2019: 14
- FWCI
- 50.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zaguan (University of Zaragoza Repository) (submittedVersion)
- Funders
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, apolipoprotein C-III, triglyceride levels, antisense therapy, hypertriglyceridemia, injection site reactions, platelet count, treatment efficacy and safety, triglyceride lowering
- MeSH terms
- Adult, Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Platelet Count, RNA, Messenger, Thrombocytopenia, Triglycerides, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.